Details for Patent: 9,227,946
✉ Email this page to a colleague
Which drugs does patent 9,227,946 protect, and when does it expire?
Patent 9,227,946 protects TRINTELLIX and is included in one NDA.
Protection for TRINTELLIX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has ninety-two patent family members in thirty-four countries.
Summary for Patent: 9,227,946
Title: | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment |
Abstract: | 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT.sub.3 and 5-HT.sub.1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients. |
Inventor(s): | Faldt; Andre (Ishoj, DK), Holm; Rene (Jyllinge, DK), de Diego; Heidi Lopez (Naerum, DK) |
Assignee: | H. Lundbeck A/S (Copenhagen-Valby, DK) |
Application Number: | 14/242,337 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,227,946 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,227,946
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-001 | Sep 30, 2013 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-002 | Sep 30, 2013 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-003 | Sep 30, 2013 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-004 | Sep 30, 2013 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,227,946
International Family Members for US Patent 9,227,946
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 061481 | ⤷ Try a Trial | |||
Argentina | 065797 | ⤷ Try a Trial | |||
Austria | E495745 | ⤷ Try a Trial | |||
Austria | E540941 | ⤷ Try a Trial | |||
Australia | 2007260355 | ⤷ Try a Trial | |||
Australia | 2008228638 | ⤷ Try a Trial | |||
Brazil | 122020011899 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |